Life Sciences

MassBio, a not-for-profit organization in Cambridge focusing on the life sciences industry in Massachusetts, appointed State Sen. Joseph Boncore, a Democrat from the First Suffolk and Middlesex District, as CEO in an announcement on Wednesday.

Marlborough medical device manufacturer Boston Scientific Corp. acquired Lumenis, an Israel-based surgical company specializing in urological lasers, in a $1.1-billion deal announced on Wednesday.

A burst in the Mass. biopharmaceutical industry over the last year has dilated the sector’s employment and real estate demand, according to a Wednesday report from MassBio.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company in Worcester, reported a net loss of $14.4 million for the company’s second quarter in an earnings report released last Monday.

ReWalk Robotics Ltd., an Israeli manufacturer of robotic medical devices for individuals with lower limb disabilities, which has its U.S. headquarters in Marlborough, announced Jeannine Lynch’s appointment as the new vice president of strategy and market access.

The Chinese manufacturer WuXi Biologics, which is building a facility at The Reactory biomanufacturing campus on Belmont Street, was approved for a 5,000-square-foot expansion by the Worcester Planning Board on Wednesday night.

Lykan Bioscience, a Hopkinton manufacturer specializing in cell-based therapies, announced Thursday a partnership with San Francisco software company Vineti.

Natick biotech firm Pillar Biosciences received premarket approval from the U.S. Food and Drug Administration for its oncoRevea Dx Lung and Colon Cancer Assay, according to a press release Thursday.

Harvard Bioscience, a life science equipment manufacturer based in Holliston, reported a net loss of $410,000 for the company’s second quarter financials in an earnings report released on Thursday.

Framingham’s SCIEX life sciences analytics company announced a partnership with Swiss biopharma group Genedata, marrying hardware and software technology to allow customers to develop drugs more rapidly.